+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target



Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target



Future Cardiology 5(2): 159-173



Lipoprotein-associated phospholipase A2 (Lp-PLA2), present in the circulation and in atherosclerotic plaque, is an inflammatory marker with potential use as a predictor of cardiovascular risk and as a therapeutic target. Although Lp-PLA2 is associated with both LDL and HDL, it is important to determine whether Lp-PLA2 has a predominantly pro- or anti-atherogenic effect. Increasing evidence suggests a proatherogenic role for Lp-PLA2. Epidemiologic and clinical evidence suggests Lp-PLA2 is an independent predictor of risk and may be superior to other inflammatory markers owing to its specificity and minimal biovariation. Lp-PLA2 inhibitors currently being investigated in clinical trials are promising novel anti-inflammatory agents with a specificity for the vascular bed and a potential for decreasing plaque vulnerability.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054139434

Download citation: RISBibTeXText

PMID: 19371190

DOI: 10.2217/14796678.5.2.159


Related references

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs 14(6): 671-679, 2005

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Review of Molecular Diagnostics 7(5): 511-517, 2007

Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy. Cardiology in Review 17(5): 222-229, 2009

Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?. Inflammation and Allergy Drug Targets 10(4): 236-246, 2011

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology 1(2): 121-125, 2001

Lipoprotein-associated Phospholipase A2: A Potential Therapeutic Target for Atherosclerosis. Current Drug Targets - Cardiovascular & Haematological Disorders 5(6): 527-532, 2005

Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Current Drug Targets. Cardiovascular and Haematological Disorders 5(6): 527-532, 2005

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Current Opinion in Pharmacology 6(2): 154-161, 2006

Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 90(5): 3100-3105, 2005

The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis. Current Atherosclerosis Reports 13(2): 132-137, 2011

Lipoprotein Associated Phospholipase A2 Assessment of a new assay for potential use as a marker of cardiovascular risk. Clinical Chemistry 48(6 Suppl.): A105, 2002

Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Archives of Internal Medicine 161(11): 1379-1380, 2001

Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer. Oncotarget 9(68): 32917-32928, 2018

Low density lipoprotein subfraction analysis in a renal transplant population A potential predictor of cardiovascular risk?. Journal of the American Society of Nephrology 12(Program and Abstract Issue): 929A, 2001

High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Current Pharmaceutical Design 16(13): 1480-1493, 2010